Fund Holdings — TCG Crossover Management, LLC

Total Portfolio Value:
$1.18B
Total Bought:
$206.62M
Total Sold:
$131.03M
Net Transaction:
+$75.59M
Securities
▲▼
SharesValue
Q2 2024
▲▼
Q3 2024
▲▼
Change
▲▼
Q2 2024
▲▼
Q3 2024
▲▼
Weight (%)
▲▼
Change
▲▼
CG Oncology, Inc.COMM(CGON)3,670,2063,670,2060$115.87M$138.48M11.73%+$22.61M
Dyne Therapeutics, Inc.COMM(DYN)2,650,1502,650,1500$93.52M$95.19M8.07%+$1.67M
Cogent Biosciences, Inc.COMM(COGT)6,964,3756,964,3750$58.71M$75.22M6.37%+$16.51M
ABIVAX Société AnonymeADRS(ABVX)6,056,5966,056,5960$80.07M$69.77M5.91%-$10.30M
Edgewise Therapeutics, Inc.COMM(EWTX)2,272,7282,112,984-159,744$40.93M$56.40M4.78%+$15.46M
Silence Therapeutics plcADRS(SLN)3,295,3503,033,560-261,790$62.61M$55.15M4.67%-$7.46M
Savara Inc.COMM(SVRA)12,362,20512,362,2050$49.82M$52.42M4.44%+$2.60M
Keros Therapeutics, Inc.COMM(KROS)879,344879,3440$40.19M$51.06M4.33%+$10.88M
Xencor, Inc.COMM(XNCR)02,427,138+2,427,138$0$48.81M4.14%+$48.81M
Tyra Biosciences, Inc.COMM(TYRA)1,989,1031,989,1030$31.81M$46.76M3.96%+$14.96M
Structure Therapeutics IncADRS694,5471,063,000+368,453$27.27M$46.66M3.95%+$19.38M
Ocular Therapeutix, Inc.COMM(OCUL)5,319,1485,319,1480$36.38M$46.28M3.92%+$9.89M
Centessa Pharmaceuticals PlcCOMM2,890,8162,890,8160$26.10M$46.22M3.92%+$20.12M
Tourmaline Bio IncCOMM1,477,5931,477,5930$19.00M$37.99M3.22%+$18.99M
Third Harmonic Bio IncCOMM02,415,000+2,415,000$0$32.72M2.77%+$32.72M
Astria Therapeutics, Inc.COMM2,761,8612,761,8610$25.13M$30.41M2.58%+$5.28M
Mineralys Therapeutics, Inc.COMM(MLYS)3,185,1852,470,265-714,920$37.27M$29.91M2.53%-$7.35M
Kura Oncology, Inc.COMM(KURA)1,423,6421,423,6420$29.31M$27.82M2.36%-$1.49M
Soleno Therapeutivs, Inc.COMM0550,000+550,000$0$27.77M2.35%+$27.77M
COMPASS Pathways plcADRS(CMPS)3,858,0003,858,0000$23.30M$24.31M2.06%+$1.00M
Disc Medicine, Inc.COMM(IRON)486,957486,9570$21.95M$23.93M2.03%+$1.98M
Fulcrum Therapeutics, Inc.COMM(FULC)05,250,000+5,250,000$0$18.74M1.59%+$18.74M
MBX Biosciences, Inc.COMM(MBX)0650,000+650,000$0$16.89M1.43%+$16.89M
Amylyx Pharmaceuticals, Inc.COMM(AMLX)04,643,812+4,643,812$0$15.05M1.27%+$15.05M
Adverum Biotechnologies, Inc.COMM02,008,339+2,008,339$0$14.10M1.19%+$14.10M
Entrada Therapeutics, Inc.COMM(TRDA)584,955584,9550$8.34M$9.35M0.79%+$1.01M
Vistagen Therapeutics, Inc.COMM(VTGN)02,676,580+2,676,580$0$8.06M0.68%+$8.06M
Tarsus Pharmaceuticals, Inc.COMM(TARS)556,317231,820-324,497$15.12M$7.62M0.65%-$7.50M
EyePoint, Inc.COMM(EYPT)922,335922,3350$8.02M$7.37M0.62%-$654.9K
Nektar TherapeuticsCOMM(NKTR)4,000,0004,000,0000$4.96M$5.20M0.44%+$240.0K
Aerovate Therapeutics IncCOMM2,240,8092,240,8090$3.72M$4.68M0.40%+$963.5K
Avalo Therapeutics, Inc.COMM(AVTX)0483,000+483,000$0$4.59M0.39%+$4.59M
Kodiak Sciences Inc.COMM(KOD)899,9991,008,158+108,159$2.11M$2.63M0.22%+$516.3K
AN2 Therapeutics, Inc.COMM1,555,1181,555,1180$3.34M$1.66M0.14%-$1.68M
Ventyx Biosciences, IncCOMM316,195316,1950$730.4K$689.3K0.06%-$41.1K
Cabaletta Bio, Inc.COMM(CABA)86,79586,7950$649.2K$409.7K0.03%-$239.6K
Adverum Biotechnologies, Inc.COMM2,008,3400-2,008,340$13.78M$0—-$13.78M
C4 Therapeutics, Inc.COMM(CCCC)1,276,5740-1,276,574$5.90M$0—-$5.90M
Madrigal Pharmaceuticals, Inc.COMM(MDGL)149,2830-149,283$41.82M$0—-$41.82M
Soleno Therapeutivs, Inc.COMM550,0000-550,000$22.44M$0—-$22.44M
Vistagen Therapeutics, Inc.COMM(VTGN)2,676,5800-2,676,580$9.31M$0—-$9.31M
Page 1 of 1
TCG Crossover Management, LLC — 13F Holdings — Q3 2024 | TickerTrail